Hunan Norchem Pharmaceutical
PrivateLast Round
Growth Equity
Dec 21, 2023
Total Funding Raised
$27.8M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Hunan Norchem Pharmaceutical operates in Healthcare & Life Sciences and is based in Changsha. Its latest recorded funding round was a Growth Equity round in December 2023.
Hunan Norchem Pharmaceutical is a biotechnology company that researches, develops, and manufactures steroid drug intermediates and active pharmaceutical ingredients (APIs) for the global pharmaceutical market.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Pharma Supply Chain, Smart Manufacturing
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hunan Norchem Pharmaceutical Comparables
Compare Hunan Norchem Pharmaceutical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hubei Goto Biopharm Co.,Ltd. | 86% | |
| Shandong Sito Bio-technology Co Ltd | 83% | |
| Tianjin Tianyao Pharmaceuticals Co Ltd | 82% |
For institutional investors. Book with your work email.
Hunan Norchem Pharmaceutical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Dec 21, 2023 | ||||
| Series B | Apr 1, 2022 | ||||
| Early Funding | Jan 28, 2022 | ||||
| Series A | Dec 18, 2015 |
For institutional investors. Book with your work email.
Hunan Norchem Pharmaceutical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cathay Capital | Growth Equity |
| CCIC Capital | Series B |
| OrbiMed | Growth Equity |
| Supernova Invest | Growth Equity |
| CICC Capital | Growth Equity |
| Zhonghe Capital | Growth Equity |
| Hunan Caixin Financial Holding Group | Growth Equity |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 427% MoM.
- Mar 8, 2025
Grew 25% QoQ, from 12 to 15 employees.
For institutional investors. Book with your work email.
Hunan Norchem Pharmaceutical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hunan Norchem Pharmaceutical's valuation, stock price, and market status.
Is Hunan Norchem Pharmaceutical a public or private company?
Hunan Norchem Pharmaceutical is a private company.
What is the current stock price of Hunan Norchem Pharmaceutical?
Hunan Norchem Pharmaceutical is a private company, so its shares have no public market price. Caplight tracks Hunan Norchem Pharmaceutical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hunan Norchem Pharmaceutical worth (valuation)?
Valuation information for Hunan Norchem Pharmaceutical is not publicly available.
Can I buy Hunan Norchem Pharmaceutical stock?
Hunan Norchem Pharmaceutical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hunan Norchem Pharmaceutical's last funding round?
Hunan Norchem Pharmaceutical's most recent funding round was Growth Equity on December 21, 2023.
Who are the main investors in Hunan Norchem Pharmaceutical?
Key investors in Hunan Norchem Pharmaceutical include OrbiMed.
Will Hunan Norchem Pharmaceutical IPO soon?
No public IPO plans have been announced for Hunan Norchem Pharmaceutical.
How can I track Hunan Norchem Pharmaceutical secondary market activity?
Caplight tracks bids, offers, and trades in Hunan Norchem Pharmaceutical's shares on secondary markets.